How do I taper off Ability (aripiprazole)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

How to Taper Off Aripiprazole (Abilify)

The most effective way to taper off aripiprazole is to gradually reduce the dose over 2-4 months using a hyperbolic tapering schedule, with dose reductions of approximately 10% per month rather than per week to minimize withdrawal symptoms.

Understanding Aripiprazole Withdrawal

Aripiprazole (Abilify) is an atypical antipsychotic that works as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and as an antagonist at 5-HT2A receptors 1. When discontinuing this medication, a careful approach is needed to prevent withdrawal symptoms and potential relapse.

Recommended Tapering Protocol

Initial Assessment

  • Evaluate current dose and duration of treatment
  • Assess risk factors for difficult withdrawal:
    • Longer duration of treatment (≥1 year)
    • Higher doses
    • History of anxiety disorders
    • Previous withdrawal symptoms

Tapering Schedule

  1. Slow Taper Rate: Reduce by approximately 10% of the original dose per month rather than per week 2

    • For example: If taking 10mg daily, reduce by 1mg per month
    • For lower doses (≤5mg), consider even smaller reductions
  2. Hyperbolic Tapering: Make smaller reductions as you reach lower doses 3

    • First reductions can be larger (e.g., 15-20% of original dose)
    • Middle reductions around 10% of original dose
    • Final reductions much smaller (5% or less of original dose)
  3. Extended Timeline: Complete taper over 2-4 months for most patients, longer for those on aripiprazole for ≥1 year 2, 4

Specific Approach Based on Current Research

  • Gradual Discontinuation: Evidence shows that tapering aripiprazole over 4-6 weeks with half-dose reductions is more effective than immediate discontinuation 4
  • Monitoring Schedule: Follow up at least monthly during the tapering process 2
  • Pause When Needed: Be prepared to temporarily pause the taper if withdrawal symptoms become significant 2

Managing Withdrawal Symptoms

Common Withdrawal Symptoms

  • Anxiety
  • Insomnia
  • Irritability
  • Nausea
  • Dizziness
  • Tremor
  • Mood changes

Symptom Management

  • Non-pharmacological approaches:

    • Regular exercise
    • Sleep hygiene practices
    • Stress management techniques
    • Cognitive behavioral therapy
  • Supportive medications (if needed):

    • Scheduled acetaminophen (not exceeding 3000mg daily) for pain/discomfort 2
    • Consider hydroxyzine for temporary anxiety/agitation
    • Trazodone for insomnia if severe

Special Considerations

Warning Signs to Slow or Pause Taper

  • Significant increase in original symptoms
  • Intolerable withdrawal symptoms
  • Suicidal ideation
  • Severe anxiety or insomnia

When to Seek Additional Support

  • If unable to tolerate even small reductions
  • If original symptoms worsen significantly
  • If new concerning symptoms develop

Important Cautions

  • Never stop aripiprazole abruptly - this increases risk of withdrawal symptoms 4
  • Inform all healthcare providers about the tapering process
  • Have a clear plan for what to do if symptoms worsen
  • Consider offering naloxone if patient is concurrently on opioids or benzodiazepines 2

By following this structured approach to tapering aripiprazole, withdrawal symptoms can be minimized while safely discontinuing the medication. The key is patience with a slow, gradual reduction schedule tailored to your specific situation.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.